The women healthcare market was valued at US$ 30.5 billion in 2021 and is likely to reach US$ 42.8 billion by 2028; it is expected to grow at a CAGR of 4.8% between 2022 and 2028.
Women's health directs to the branch of medicine that focuses on treating and diagnosing diseases and conditions affecting women's physical and emotional well-being. Women usually experience unique health care challenges and are more likely to be diagnosed with certain diseases than men. Chronic diseases and conditions such as heart disease, cancer, and diabetes are the leading causes of death among women. Other health concerns impacting women include maternal health issues, urinary tract infections, sexual health, and osteoporosis.
MARKET DYNAMICS
The small and big companies operating in the women healthcare market are adopting various strategies, including regional expansion and technological advancements, to increase their market share. Growing incidence of chronic health conditions among women, rising government initiatives to restrain population growth, and increasing demand for contraceptives to control unintended pregnancies are other factors propelling the market growth. Moreover, key players' growing focus on R&D for developing advanced products is a significant market driver. Long-term extreme adverse effects of oral contraceptive pills, such as stroke, decreased libido, blood clots, vaginal discharge, and augmented risk of breast cancer, may limit usage and lead to restrictions by regulatory agencies. Such factors may hinder the market growth during the forecast period.
MARKET SCOPE
The "Global Women Healthcare market Analysis to 2028" report aims to provide an overview of the women healthcare market with detailed market segmentation based on drug and application. The report provides key statistics based on the financial performances of the leading market players. It also offers key trends and opportunities in the market.
Strategic Insights
MARKET SEGMENTATION
The global women healthcare market is segmented based on drug and application. Based on drug, the market is segmented into EVISTA, XGEVA, Prolia, Mirena, Zometa, Reclast/Aclasta, and others. In terms of application, the market is segmented into hormonal infertility, postmenopausal osteoporosis, endometriosis, contraceptives, menopause, and others.
REGIONAL FRAMEWORK
The global women healthcare market is segmented into five major regions—North America, Europe, Asia Pacific (APAC), Middle East & Africa (MEA), and South & Central America. The report covers analysis and forecast of 18 countries globally, along with trends and opportunities prevailing in all the above-mentioned regions.
North America dominates the women healthcare market. The market in North America is majorly driven by the growing prevalence of polycystic ovary syndrome (PCOS) and postmenopausal osteoporosis, increasing median age of first-time pregnancies, and rising healthcare spending in the US and Canada. According to the World Health Organization (WHO), in 2021, globally, around 190 million women of reproductive age were affected by endometriosis. Also, the increased awareness and familiarity regarding contraceptives among women and the easy access to modern contraception compared to developing countries are fueling the market growth in this region.
The below figure shows the revenue growth trend in the North America women healthcare market:
(image)
Source: The Insight Partners Analysis
The report analyzes factors such as drivers, restraints, opportunities, and future trends, which impact the growth of the women healthcare market. The report also provides a PEST analysis highlighting the factors affecting the women healthcare market in these regions.
IMPACT OF COVID-19 PANDEMIC
According to the World Health Organization (WHO), as of August 2022, there were 596,873,121 confirmed cases of COVID-19 and 6,459,684 deaths. The highest number of deaths was in the Americas, followed by Europe and Southeast Asia. Due to economic uncertainty caused by COVID-19, limited transit options and travel limitations created impediments to international trade and transportation, affecting the supply chain for women's health diagnostics and temporarily lowering demand. The COVID-19 pandemic disrupted the supply chain of contraceptives, thus affecting sexual and reproductive health services. Also, due to COVID-19, several health services was forced to suspended or postponed. Thus, during the initial days, the COVID-19 pandemic had a negative impact on the women health care market.
MARKET PLAYERS
The report covers key developments in the women healthcare market. Various companies are focusing on organic growth strategies such as product launches, product approvals, and patents and events. In addition, acquisitions, partnerships, and collaborations are among the inorganic growth strategies witnessed in the market. These activities have paved the way for the expansion of business and the customer base of market players. The players operating in the women healthcare market are anticipated to experience lucrative growth opportunities in the future owing to the rising demand for women health care products.
The report also includes the profiles of key women healthcare market companies along with their SWOT analysis and market strategies. In addition, it focuses on leading industry players with information such as company profiles, components and services offered, financial information of the last three years, and key development in the past five years.
Below mentioned is the list of a few companies engaged in the women healthcare market.
-Bayer AG
-Allergan plc
-Merck & Co.
-Pfizer Inc.
-Amgen Inc.
-Agile Therapeutics Inc.
-Ferring Pharmaceuticals
-Mylan N.V.
-Lupin LimitedÂ
-Blairex Laboratories
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
(image)